Beckman Coulter Acquires Cogenics
Frequently Asked Questions

1. Who should customers call for service support?
Initially customers should contact the respective business where their work is being performed. We will be sure to communicate any changes to this.

2. Will there be any disruption to service and support?
Please be assured that we will strive to ensure that there will be minimal disruption to any ongoing projects you have in progress with either Agencourt or Cogenics.

3. What is the benefit for Agencourt and Cogenics customers?
We will be able to offer our customers a broad range of genomic services including Sample Preparation, Genotyping, Gene Expression, Biologics Efficacy and Safety Testing, as well as comprehensive sequencing service offerings.

4. Where will the business headquarters be located?
The business headquarters will be located in Beverly, Massachusetts.

5. How does the acquisition fit with Beckman Coulter's strategy?
Beckman Coulter is a leader in biomedical testing - and the merged company will be positioned as a leading provider of genomic services. As such, it will enable discovery, detection, and diagnostics to improve human health, supporting Beckman Coulter's inspiration to improve patient health and reduce the cost of care.

6. When will the acquisition close?
We expect very soon, early in April, 2009.

7. What values will drive the integration of the two companies?
The combination of Agencourt and Cogenics integrates two customer-focused businesses. Both share a passion and commitment to delivering outstanding service. Both also value integrity, leadership, and teamwork, and strive to provide an enjoyable work environment and make a positive impact in the communities in which employees live and work.